USC Norris Comprehensive Cancer Center

Keck School of Medicine of USC

# 12<sup>th</sup> Annual USC Multi-Disciplinary Breast Cancer Symposium

January 25, 2025
Live Conference | SLS Beverly Hills
Los Angeles, California

Presented By:
USC Office of Continuing Medical Education



# PROGRAM AGENDA

7:00 am	Registration Opens and	Session II	l:		
	Continental Breakfast	Moderator: Eric L. Chang, MD			
7:55 am	Welcome and Opening Remarks	12:45 pm	Oncofertility		
	Eric L. Chang, MD and		Natalia Llarena, MD		
	Stephen F. Sener, MD	1:15 pm	Results of the NATALEE Trial		
			Nicholas P. McAndrew, MD, MSCE		
Session I:		1:45 pm	Anti-Mullerian Hormone and		
Moderator	: Daphne Stewart, MD, MS		RxPONDER		
8:00 am	Race and RxPONDER		Andrew K Godwin, PhD		
	Yara Abdou, MD	2:15 pm	Case Presentation and Discussion		
8:30 am	Tumor Micro Environment		Katharine Armstrong, MD, Alexa		
	Associated with Race, Ethnicity		Griffiths, MD and Kaye Lu, MD		
	Evanthia Roussos Torres, MD, PhD	2:30 pm	Break		
9:00 am	Case Presentation and Discussion				
9:15 am	Minimal Residual Disease and	Session IV:			
	ct-DNA	Moderato	Moderator: Jason C. Ye, MD		
	Daniel G. Stover, MD	2:45 pm	Axillary Management		
9:45 am	Mechanisms of Resistance to		Tari A. King, MD		
	Antiestrogen Therapy in ER+	3:15 pm	Omission of Radiation for Early-		
	Breast Cancer		Stage Breast Cancers. DEBRA or		
	Carlos L. Arteaga, MD		MA.39		
10:15 am	Case Presentation and Discussion		Tim Whelan, MD		
	Grant Jirka, MD and Jade Law, MD	3:45 pm	Evolution of Post-Mastectomy		
10:30 am	Break		Radiation Therapy for Breast Cancer		
			Rachel B. Jimenez, MD		
Session II	:	4:15 pm	Case Presentation and Discussion		
Moderator: Stephen F. Sener, MD			Christine Yang, MD		
10:45 am	Antibody Drug Conjugates in	4:30 pm	Closing Remarks		
	Advanced HR+/HER2- Breast Cancer	4:35 pm	Adjourn		
	and TN Breast Cancer				
	Rebecca Shatsky, MD				
11:15 am	Improving Options in Hormone				

The 12th Anniversary:

**Receptor-Positive Metastatic** 

Alexa Griffiths, MD and Kaye Lu, MD

Breast Cancer
William J. Gradishar, MD

11:45 am Case Presentation and Discussion
Katharine Armstrong, MD,

12:00 pm Lunch

USC Multi-Disciplinary Breast Cancer Symposium is supported by an endowed lectureship known as
The Henry L. Jaffe, MD Annual Oration in Therapeutic Radiology

# FACULTY —

### PROGRAM ORGANIZING COMMITTEE

### Eric L. Chang, MD, FASTRO, FARS

Professor, Chair, Course Director Department of Radiation Oncology Keck School of Medicine of USC

Stephen F. Sener, MD, FACS, FSSO

Professor of Surgery Breast, Endocrine, and Soft Tissue Surgery Division Department of Surgery

> Keck School of Medicine of USC Chief of Surgery

Los Angeles General Medical Center

### Daphne Stewart, MD, MS

Professor of Medicine

Breast Oncology, Division of Medical Oncology Department of Medicine

Keck School of Medicine of USC

Jason C. Ye, MD

Associate Professor of Clinical Radiation Oncology **Director of Clinical Operations** Department of Radiation Oncology Keck School of Medicine of USC

### **GUEST FACULTY**

### Yara Abdou, MD

Assistant Professor, Division of Oncology Director of Breast Cancer Clinical Trials Program, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center Chapel Hill, NC

### Carlos L. Arteaga, MD

Professor of Medicine Director, UTSW Harold C. Simmons Comprehensive Cancer Center Annette Simmons Distinguished University Chair in Breast Cancer Research Associate Dean of Oncology Programs **UT Southwestern Medical Center** 

Dallas, TX

### Andrew K. Godwin, PhD

Chancellors Distinguished Chair in Biomedical Sciences Endowed Professor.

Director, Molecular Oncology Division Director, Genomic Diagnostics Deputy Director, University of Kansas NCI-Comprehensive Designated Cancer Center Founding Director.

Kansas Institute for Precision Medicine CORE Founding Director, Center for Genetic Services and Health Equity

Department of Pathology & Laboratory Medicine University of Kansas Medical Center Kansas City, KS

### William J. Gradishar, MD, FASCO, FACP

Betsy Bramsen Professor of Breast Oncology Professor of Medicine Deputy Director, Clinical Network Director, Maggie Daley Center for Women's Cancer Care Robert H. Lurie Comprehensive Cancer Center of

Northwestern University, Feinberg School of Medicine Chicago, IL

### Rachel Jimenez, MD

Department of Radiation Oncology Massachusetts General Hospital Associate Professor, Radiation Oncology Harvard Medical School Boston, MA

### Tari A. King, MD, FASCO, FSSO

Vice Chair for Multidisciplinary Oncology. Department of Surgery Chief, Division of Breast Surgery, Brigham and Women's Hospital Dana-Farber/Brigham Cancer Center Anne E. Dyson Professor of Surgery in the Field of Women's Cancers Harvard Medical School Boston, MA

### Nicholas P. McAndrew, MD, MSCE

Assistant Clinical Professor, Medicine David Geffen School of Medicine, UCLA Santa Monica Parkside Cancer Care Santa Monica, CA

### Rebecca Shatsky, MD

La Jolla, CA

Associate Professor of Medicine Breast Medical Oncology Co-Team Leader Scientific Director Inflammatory and Triple Negative Breast Cancer Program UC San Diego Comprehensive Breast Health Team

### Daniel G. Stover, MD

Associate Professor, Medical Oncology Department of Medical Oncology Director, Translational Breast Cancer Associate Professor, Department of Biomedical Informatics The Ohio State University Comprehensive Cancer Centern Columbus, OH

### Tim Whelan, MD

Professor, Oncology Faculty of Health Sciences Canada Research Chair in Breast Cancer Research McMaster University Hamilton, Ontario, Canada

### KECK SCHOOL OF MEDICINE FACULTY

## Natalia Llarena, MD

Adjunct Clinical Assistant Professor of Obstetrics and Gynecology Department of Obstetrics and Gynecology

### **USC FELLOWS -**

Katharine Armstrong, MD Alexa Griffiths, MD Kaye Lu, MD

Grant Jirka, MD

Jade Law, MD

### **Evanthia Roussos Torres MD. PhD** Assistant Professor of Medicine

Division of Oncology Co-Leader Tumor Immune Microenvironment Program

### USC RESIDENT

Christine Yang, MD

# COURSE DESCRIPTION

This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include oncofertility, breast pathology, surgical oncology, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.

Over the past year, advances in clinical trials have demonstrated the utility of antibody-drug conjugates, immunotherapy, genomic assays in hormone receptor-positive breast cancer, and downstaging surgical management of the axilla. These developments, along with data on resistance to endocrine therapy, therapy targeting the HER2 axis, and the prognostic or predictive value of minimal residual disease in the bloodstream after treatment, make individualized management decisions increasingly important in treating patients with breast cancer. Newer radiation therapy treatment strategies and clinical trials in radiation oncology continue to evolve. These breakthroughs allow personalized breast cancer treatments to maximize benefits and minimize treatment toxicities.

The understanding of the HER2 receptor continues to evolve. Key talks in medical oncology will focus on HER2+ breast cancer therapeutics in the adjuvant setting, the use of newer agents in metastatic ER+ cancers, and the evolution of immunotherapy as a central theme in the treatment of triple-negative breast cancer. New data on the Anti-Mullerian Hormone assay, an evolving factor predictive of benefit from chemotherapy from the RxPONDER trial, will also be presented.

# LEARNING OBJECTIVES

- Assess decision-making process in surgical management of the axilla.
- Classify evolving concepts in treatment of HER2-low breast cancer.
- Explain the biology of HER2 axis and its role in treating metastatic cancer.
- Define the role of CDK inhibitors in treating metastatic and resistant ER+ cancers.
- · Incorporate the evolving role of clinical trials in radiation therapy.
- Explain the importance of fertility preservation during breast cancer treatment.
- Appreciate the evolution of antibody drug conjugates as a treatment strategy for advanced breast cancer.
- Recognize an evolving new hormone assay to predict benefit from adjuvant chemotherapy.
- Understand the evolution of the identification of minimal residual disease in the blood after treatment as a prognostic/predictive factor in survival.

# TARGET AUDIENCE

This conference is designed for practicing primary care physicians, medical oncologists, radiation oncologists, surgical oncologists, radiologists, residents and fellows in oncology training programs, as well as allied health providers including oncology nurses, mid-level providers (APN and PA), radiation therapists (RTT), and any other clinicians interested or involved in the management and treatment of breast cancer.

# **ACCREDITATION STATEMENT**

The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

# **CREDIT DESIGNATION**

The Keck School of Medicine of the University of Southern California designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The following may apply AMA PRA Category 1 Credit(s)™ for license renewal: Registered Nurses may report up to 7.25 credit hour(s) toward the CME requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number. Physician Assistants: The National Commission on Certification of Physician Assistants states that AMA PRA Category 1 Credits™ accredited courses are acceptable CME requirements for recertification.

# **REGISTRATION FORM**

Early-bird price for live registration ends January 21, 2025 at 12:00pm PST. To register after January 21: please register on-site.

Tuition:						
MD/DO		Early-Bird	After Jan. 21st			
MD/DO		□ \$175 □ \$100	□ \$225 □ \$125			
NP/PA/APP RN/AH		\$100	□ \$125			
Students, Reside	nts Fellows		\$35			
Students, Reside	iits, i citows	<b>4</b> 455	<b>4 4 5 5</b>			
Cancellation:	January 21, 1 In the event	Cancellations must be received by the USC Office of CME (fax or email) by January 21, 12:00 pm PST for a refund. A \$50 cancellation fee will be applied. In the event of course cancellation by conference organizers, all registration fees will be fully refunded. USC will not refund any travel costs incurred.				
Location:	SLS Beverly I	SLS Beverly Hills, 465 S. La Cienega Boulevard, Los Angeles, CA 90048				
Parking:	Parking: Valet overnight parking: \$60 Discounted day parking rate: \$20 per car, mention USC Breast Cancer Conference.					
Hotel:	Rate: \$379, January 23-25, 2025. For reservations, call (310) 247-0400 before January 10, 2025.					
Register:	Mail: 1540 Alcazar Street, CHP 223, Los Angeles, CA 90033  Mail-in registration must be postmarked by January 21, 2025; Online: keckusc.cloud-cme.com/breastcancer2025 Phone: (323) 442-2555   Fax: 1 (323) 442-3734   AMEX, Mastercard or Visa Email: usccme@usc.edu					
On-site:	Live registration: Available January 25, 7:00 am, SLS Beverly Hills.					
NAME DEGREE						
MEDICAL LICENSI	E NUMBER					
TELEPHONE						
ADDRESS						
CITY		ST/	ATE	ZIP		
SPECIALTY						
EMAIL ADDRESS*						
INSTITUTIONAL AFFILIATION						
Method of Paym No cash payment a Check (Check p	ent: accepted. payable to USC		be postmarked by Janua by fax/mail/phone only)	ary 21, 2025)		
CREDIT CARD NUMBER						
EXPIRATION DATE		SEC	CURITY CODE			
AUTHORIZED SIGNED			AMOUNT &			

# Keck School of Medicine of USC

Office of Continuing Medical Education 1540 Alcazar Street, CHP 223 Los Angeles, CA 90033



12<sup>th</sup> Annual USC Multi-Disciplinary Breast Cancer Symposium January 25, 2025

Live Conference SLS Beverly Hills 465 S. La Cienega Boulevard Los Angeles, CA 90048

Non-Profit U.S. Postage PAID University of Southern California